JIA-HORNG KAO2021-09-042021-09-0420160929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960264071&doi=10.1016%2fj.jfma.2015.06.012&partnerID=40&md5=8fbd9c4b0665a41194a2790907cdaafdhttps://scholars.lib.ntu.edu.tw/handle/123456789/581921[SDGs]SDG3asunaprevir plus beclabuvir plus daclatasvir; boceprevir; elbasvir plus grazoprevir; interferon; ledipasvir plus sofosbuvir; ombitasvir plus paritaprevir plus ritonavir; ribavirin; simeprevir; sofosbuvir; telaprevir; alpha interferon; antivirus agent; ribavirin; hepatitis C; Hepatitis C virus genotype 1; human; Short Survey; single nucleotide polymorphism; Taiwan; treatment response; drug effects; genetics; Hepacivirus; hepatitis C; public health; Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Public Health; Ribavirin; Taiwanshort survey10.1016/j.jfma.2015.06.012262286872-s2.0-84960264071